MBC results for daptomycin linezolid and vancomycin tested against S. aureus
| Antimicrobial agent | No. of isolates (cumulative %) with MBC at: |
||||||||
|---|---|---|---|---|---|---|---|---|---|
| ≤0.12 | 0.25 | 0.5 | 1 | 2 | 4 | 8 | 16 | ≥32 | |
| Daptomycin | |||||||||
| MRSA-WT (101) | 0 (0) | 29 (29) | 64 (92) | 7 (99) | 1 (100) | − | − | − | − |
| hVISA (64)c | 0 (0) | 1 (2) | 32 (52) | 30 (98) | 1 (100) | − | − | − | − |
| VISA (37) | 0 (0) | 0 (0) | 2 (5) | 23 (65) | 9 (92) | 3 (100) | − | − | − |
| VRSA (5) | 0 (0) | 0 (0) | 4 (80) | 1 (100) | − | − | − | − | − |
| Linezolid | |||||||||
| MRSA-WT (101)a | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (1) | 0 (1) | 100 (100) |
| hVISA (64)c | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 64 (100) |
| VISA (37) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 2 (5) | 0 (5) | 0 (5) | 0 (5) | 35 (100) |
| VRSA (5) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 5 (100) |
| Vancomycinb | |||||||||
| MRSA-WT (101) | NTc | NT | 2 (2) | 38 (40) | 23 (62) | 9 (71) | 14 (85) | 3 (88) | 12 (100) |
| hVISA (64)c | NT | NT | 0 (0) | 3 (3.0) | 9 (12) | 3 (17) | 2 (20) | 4 (24) | 43 (100) |
| VISA (37) | NT | NT | 0 (0) | 0 (0) | 0 (0) | 2 (5) | 1 (8) | 0 (8) | 34 (100) |
a
Clinical MRSA isolates with vancomycin MIC ≤ 2 mg/L (homogeneous populations) collected from medical centres worldwide in 2003.
b
MBC was not evaluated on VRSA strains (five strains with vancomycin MIC >32mg/L)
c
NT not tested